Verrica CCO Joe Bonaccorso resigns effective Aug 30, 2024; consulting role through Aug 2025

Verrica Pharmaceuticals Inc.

Joe Bonaccorso resigns as Chief Commercial Officer effective August 30, 2024.
Separation benefits include 12 months base salary and up to 12 months COBRA coverage.
Consulting Agreement runs through August 30, 2025, with no cash compensation; outstanding equity continues vesting.
Company expects to enter into Release and Consulting Agreements with Bonaccorso.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Joe Bonaccorso

Chief Commercial Officer

VRCA · Verrica Pharmaceuticals Inc.

Effective: 2024-08-30
Filed: August 27, 2024, 7:59 PM ET

On August 21, 2024, Mr. Bonaccorso notified Verrica Pharmaceuticals Inc. (the “Company”) that he will resign from his position as Chief Commercial Officer of the Company, effective August 30, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Joe Bonaccorso resigned as Chief Commercial Officer at Verrica Pharmaceuticals Inc..

Action: resigned
Role: Chief Commercial Officer

Exact text from the filing

On August 21, 2024, Mr. Bonaccorso notified Verrica Pharmaceuticals Inc. (the “Company”) that he will resign from his position as Chief Commercial Officer of the Company, effective August 30, 2024.

View on SEC.gov

Verrica Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-207814

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.